<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33582607</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2163</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>362</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cellular immunology</Title>
          <ISOAbbreviation>Cell Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases.</ArticleTitle>
        <Pagination>
          <StartPage>104300</StartPage>
          <MedlinePgn>104300</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cellimm.2021.104300</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0008-8749(21)00019-8</ELocationID>
        <Abstract>
          <AbstractText>Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which have been characterized for their immunosuppressive capacity through multiple mechanisms. These cells have been extensively studied in the field of tumor immunity. Emerging evidence has highlighted its essential role in maintaining immune tolerance in transplantation and autoimmunity. Because of their robust immune inhibitory activities, there has been growing interest in MDSC-based cellular therapy. Various pre-clinical studies have demonstrated that the adoptive transfer of MDCS represented a promising therapeutic strategy for immune-related disorders. In this review, we summarize relevant studies of MDSC-based cell therapy in transplantation and autoimmune diseases and discuss the challenges and future directions for clinical application of MDSC-based cell therapy.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jilu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States. Electronic address: jzhang2@houstonmethodist.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hodges</LastName>
            <ForeName>Alan</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States; Texas A&amp;M College of Medicine, Bryan, TX, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Shu-Hsia</ForeName>
            <Initials>SH</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States; Texas A&amp;M College of Medicine, Bryan, TX, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Ping-Ying</ForeName>
            <Initials>PY</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States; Texas A&amp;M College of Medicine, Bryan, TX, United States. Electronic address: ppan@houstonmethodist.org.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 CA127483</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA188610</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA204191</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA208703</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Immunol</MedlineTA>
        <NlmUniqueID>1246405</NlmUniqueID>
        <ISSNLinking>0008-8749</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019264" MajorTopicYN="N">Adoptive Transfer</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019737" MajorTopicYN="N">Transplants</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Autoimmune disease</Keyword>
        <Keyword MajorTopicYN="Y">Cellular therapy</Keyword>
        <Keyword MajorTopicYN="Y">Myeloid-derived suppressor cell</Keyword>
        <Keyword MajorTopicYN="Y">Transplantation</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest. None</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>20</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33582607</ArticleId>
        <ArticleId IdType="mid">NIHMS1673835</ArticleId>
        <ArticleId IdType="pmc">PMC8019491</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cellimm.2021.104300</ArticleId>
        <ArticleId IdType="pii">S0008-8749(21)00019-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kumar V, Patel S, Tcyganov E, Gabrilovich DI, The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment, Trends Immunol, 37 (2016) 208–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4775398</ArticleId>
            <ArticleId IdType="pubmed">26858199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S, Myeloid-derived suppressor cells as regulators of the immune system, Nature reviews. Immunology, 9 (2009) 162–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janikashvili N, Trad M, Gautheron A, Samson M, Lamarthee B, Bonnefoy F, Lemaire-Ewing S, Ciudad M, Rekhviashvili K, Seaphanh F, Gaugler B, Perruche S, Bateman A, Martin L, Audia S, Saas P, Larmonier N, Bonnotte B, Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes, J Allergy Clin Immunol, 135 (2015) 1614–1624 e1614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25630940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casacuberta-Serra S, Pares M, Golbano A, Coves E, Espejo C, Barquinero J, Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes, Immunol Cell Biol, 95 (2017) 538–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28108746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lechner MG, Liebertz DJ, Epstein AL, Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells, Journal of immunology, 185 (2010) 2273–2284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2923483</ArticleId>
            <ArticleId IdType="pubmed">20644162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomic S, Joksimovic B, Bekic M, Vasiljevic M, Milanovic M, Colic M, Vucevic D, Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets, Front Immunol, 10 (2019) 475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6431635</ArticleId>
            <ArticleId IdType="pubmed">30936876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joyce D, Fujino M, Morita M, Araki R, Fung J, Qian S, Lu L, Li XK, Induced pluripotent stem cells-derived myeloid-derived suppressor cells regulate the CD8(+) T cell response, Stem Cell Res, 29 (2018) 32–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29574174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao X, Yakala GK, van den Hil FE, Cochrane A, Mummery CL, Orlova VV, Differentiation and Functional Comparison of Monocytes and Macrophages from hiPSCs with Peripheral Blood Derivatives, Stem Cell Reports, 12 (2019) 1282–1297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6565887</ArticleId>
            <ArticleId IdType="pubmed">31189095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sasaki H, Wada H, Baghdadi M, Tsuji H, Otsuka R, Morita K, Shinohara N, Seino K, New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts, Transplantation, 99 (2015) 2301–2310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26360665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao X, van den Hil FE, Mummery CL, Orlova VV, Generation and Functional Characterization of Monocytes and Macrophages Derived from Human Induced Pluripotent Stem Cells, Curr Protoc Stem Cell Biol, 52 (2020) e108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7154707</ArticleId>
            <ArticleId IdType="pubmed">32159928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Senju S, Haruta M, Matsumura K, Matsunaga Y, Fukushima S, Ikeda T, Takamatsu K, Irie A, Nishimura Y, Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy, Gene Ther, 18 (2011) 874–883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21430784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H, The terminology issue for myeloid-derived suppressor cells, Cancer research, 67 (2007) 425; author reply 426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1941787</ArticleId>
            <ArticleId IdType="pubmed">17210725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI, Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards, Nat Commun, 7 (2016) 12150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4935811</ArticleId>
            <ArticleId IdType="pubmed">27381735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn JI, Nagaraj S, Collazo M, Gabrilovich DI, Subsets of myeloid-derived suppressor cells in tumor-bearing mice, Journal of immunology, 181 (2008) 5791–5802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2575748</ArticleId>
            <ArticleId IdType="pubmed">18832739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K, Lv M, Chang YJ, Zhao XY, Zhao XS, Zhang YY, Sun YQ, Wang ZD, Suo P, Zhou Y, Liu D, Zhai SZ, Hong Y, Wang Y, Zhang XH, Xu LP, Liu KY, Huang XJ, Early myeloid-derived suppressor cells (HLA-DR(−)/(low)CD33(+)CD16(−)) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT, J Hematol Oncol, 12 (2019) 31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6423891</ArticleId>
            <ArticleId IdType="pubmed">30885244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF, Korangy F, S100A9 a new marker for monocytic human myeloid-derived suppressor cells, Immunology, 136 (2012) 176–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3403264</ArticleId>
            <ArticleId IdType="pubmed">22304731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, Roth J, Gabrilovich DI, Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein, The Journal of experimental medicine, 205 (2008) 2235–2249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2556797</ArticleId>
            <ArticleId IdType="pubmed">18809714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G, Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells, Journal of immunology, 181 (2008) 4666–4675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810501</ArticleId>
            <ArticleId IdType="pubmed">18802069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI, Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients, Sci Immunol, 1 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5391495</ArticleId>
            <ArticleId IdType="pubmed">28417112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sangaletti S, Talarico G, Chiodoni C, Cappetti B, Botti L, Portararo P, Gulino A, Consonni FM, Sica A, Randon G, Di Nicola M, Tripodo C, Colombo MP, SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities, Front Immunol, 10 (2019) 1369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6596449</ArticleId>
            <ArticleId IdType="pubmed">31281314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papaspyridonos M, Matei I, Huang Y, do Rosario Andre M, Brazier-Mitouart H, Waite JC, Chan AS, Kalter J, Ramos I, Wu Q, Williams C, Wolchok JD, Chapman PB, Peinado H, Anandasabapathy N, Ocean AJ, Kaplan RN, Greenfield JP, Bromberg J, Skokos D, Lyden D, Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation, Nat Commun, 6 (2015) 6840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4423225</ArticleId>
            <ArticleId IdType="pubmed">25924227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melief J, Pico de Coana Y, Maas R, Fennemann FL, Wolodarski M, Hansson J, Kiessling R, High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma, Cancer Immunol Immunother, 69 (2020) 513–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7113206</ArticleId>
            <ArticleId IdType="pubmed">31953577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talmadge JE, Gabrilovich DI, History of myeloid-derived suppressor cells, Nature reviews. Cancer, 13 (2013) 739–752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4358792</ArticleId>
            <ArticleId IdType="pubmed">24060865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao L, Pan S, Zhang QP, Jamal M, Rushworth GM, Xiong J, Xiao RJ, Sun JX, Yin Q, Wu YJ, Lie AKW, Emerging Role of Myeloid-derived Suppressor Cells in the Biology of Transplantation Tolerance, Transplantation, 104 (2020) 467–475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31596739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ochando J, Conde P, Utrero-Rico A, Paz-Artal E, Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation, Front Immunol, 10 (2019) 374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6414442</ArticleId>
            <ArticleId IdType="pubmed">30894860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Aveni M, Notarantonio AB, Bertrand A, Boulange L, Pochon C, Rubio MT, Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation, Front Immunol, 11 (2020) 989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7256196</ArticleId>
            <ArticleId IdType="pubmed">32528476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koehn BH, Blazar BR, Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation, J Leukoc Biol, 102 (2017) 335–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5505741</ArticleId>
            <ArticleId IdType="pubmed">28148718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luyckx A, Schouppe E, Rutgeerts O, Lenaerts C, Fevery S, Devos T, Dierickx D, Waer M, Van Ginderachter JA, Billiau AD, G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells, Clin Immunol, 143 (2012) 83–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22341087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Q, Liu H, Liang X, Yang T, Fan Z, Huang F, Ling Y, Liao X, Xuan L, Xu N, Xu X, Ye J, Liu Q, Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia, J Hematol Oncol, 10 (2017) 135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5496166</ArticleId>
            <ArticleId IdType="pubmed">28676100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv M, Zhao XS, Hu Y, Chang YJ, Zhao XY, Kong Y, Zhang XH, Xu LP, Liu KY, Huang XJ, Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation, Am J Hematol, 90 (2015) E9–E16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25303038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vendramin A, Gimondi S, Bermema A, Longoni P, Rizzitano S, Corradini P, Carniti C, Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 20 (2014) 2049–2055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25246295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hongo D, Tang X, Baker J, Engleman EG, Strober S, Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance, Am J Transplant, 14 (2014) 2467–2477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4205183</ArticleId>
            <ArticleId IdType="pubmed">25311657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dugast AS, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N, Vuillefroy de Silly R, Usal C, Smit H, Martinet B, Thebault P, Renaudin K, Vanhove B, Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion, Journal of immunology, 180 (2008) 7898–7906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18523253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luan Y, Mosheir E, Menon MC, Wilson D, Woytovich C, Ochando J, Murphy B, Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion, Am J Transplant, 13 (2013) 3123–3131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24103111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hock BD, Mackenzie KA, Cross NB, Taylor KG, Currie MJ, Robinson BA, Simcock JW, McKenzie JL, Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells, Nephrol Dial Transplant, 27 (2012) 402–410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21617199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jenq RR, van den Brink MR, Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer, Nature reviews. Cancer, 10 (2010) 213–221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20168320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara JLM, Levine JE, Reddy P, Holler E, Graft-versus-host disease, The Lancet, 373 (2009) 1550–1561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2735047</ArticleId>
            <ArticleId IdType="pubmed">19282026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blazar BR, Murphy WJ, Abedi M, Advances in graft-versus-host disease biology and therapy, Nature reviews. Immunology, 12 (2012) 443–458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3552454</ArticleId>
            <ArticleId IdType="pubmed">22576252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inamoto Y, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Deeg HJ, Storb RF, Appelbaum FR, Storer BE, Martin PJ, Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation, Blood, 118 (2011) 456–463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3138695</ArticleId>
            <ArticleId IdType="pubmed">21633087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michallet M, Sobh M, Barraco F, Thomas X, Balsat M, Lejeune C, Ducastelle S, Renault M, Tedone N, Labussiere H, Nicolini F-E, Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors, Blood, 128 (2016) 5786–5786.</Citation>
        </Reference>
        <Reference>
          <Citation>MacDonald KP, Rowe V, Clouston AD, Welply JK, Kuns RD, Ferrara JL, Thomas R, Hill GR, Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells, Journal of immunology, 174 (2005) 1841–1850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15699110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morecki S, Gelfand Y, Yacovlev E, Eizik O, Shabat Y, Slavin S, CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 (2008) 973–984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18721760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joo YD, Lee SM, Lee SW, Lee WS, Lee SM, Park JK, Choi IW, Park SG, Choi I, Seo SK, Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism, Immunology, 128 (2009) e632–640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2753900</ArticleId>
            <ArticleId IdType="pubmed">19740324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Santos e Sousa P, Bruneau J, Fouquet G, Zavala F, Alegria-Prevot O, Garfa-Traore M, Suarez F, Trebeden-Negre H, Mohty M, Bennett CL, Chakraverty R, Hermine O, Rubio MT, G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease, Sci Transl Med, 7 (2015) 281ra242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25834108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z, French DL, Ma G, Eisenstein S, Chen Y, Divino CM, Keller G, Chen SH, Pan PY, Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells, Stem cells, 28 (2010) 620–632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4370270</ArticleId>
            <ArticleId IdType="pubmed">20073041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR, Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13, Blood, 116 (2010) 5738–5747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3031417</ArticleId>
            <ArticleId IdType="pubmed">20807889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR, GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells, Blood, 126 (2015) 1621–1628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4582338</ArticleId>
            <ArticleId IdType="pubmed">26265697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koehn BH, Saha A, McDonald-Hyman C, Loschi M, Thangavelu G, Ma L, Zaiken M, Dysthe J, Krepps W, Panthera J, Hippen K, Jameson SC, Miller JS, Cooper MA, Farady CJ, Iwawaki T, Ting JP, Serody JS, Murphy WJ, Hill GR, Murray PJ, Bronte V, Munn DH, Zeiser R, Blazar BR, Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD, Blood, 134 (2019) 1670–1682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6871306</ArticleId>
            <ArticleId IdType="pubmed">31533918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messmann JJ, Reisser T, Leithauser F, Lutz MB, Debatin KM, Strauss G, In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity, Blood, 126 (2015) 1138–1148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26185131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karimi MA, Bryson JL, Richman LP, Fesnak AD, Leichner TM, Satake A, Vonderheide RH, Raulet DH, Reshef R, Kambayashi T, NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT, Blood, 125 (2015) 3655–3663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4458804</ArticleId>
            <ArticleId IdType="pubmed">25788701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Chen HM, Ma G, Zhou Z, Raulet D, Rivera AL, Chen SH, Pan PY, The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells, Leukemia, 33 (2019) 2078–2089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6687551</ArticleId>
            <ArticleId IdType="pubmed">30737483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park MY, Lim BG, Kim SY, Sohn HJ, Kim S, Kim TG, GM-CSF Promotes the Expansion and Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic Graft-vs.-Host Disease, Front Immunol, 10 (2019) 183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6399310</ArticleId>
            <ArticleId IdType="pubmed">30863394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia MR, Ledgerwood L, Yang Y, Xu J, Lal G, Burrell B, Ma G, Hashimoto D, Li Y, Boros P, Grisotto M, van Rooijen N, Matesanz R, Tacke F, Ginhoux F, Ding Y, Chen SH, Randolph G, Merad M, Bromberg JS, Ochando JC, Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice, The Journal of clinical investigation, 120 (2010) 2486–2496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2898596</ArticleId>
            <ArticleId IdType="pubmed">20551515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T, Nakao T, Yoshimura N, Ashihara E, Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells, Am J Transplant, 15 (2015) 2364–2377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25943210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Shen XF, Cao K, Ding J, Kang X, Guan WX, Ding YT, Liu BR, Du JF, Dexamethasone-Induced Myeloid-Derived Suppressor Cells Prolong Allo Cardiac Graft Survival through iNOS- and Glucocorticoid Receptor-Dependent Mechanism, Front Immunol, 9 (2018) 282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5818399</ArticleId>
            <ArticleId IdType="pubmed">29497426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Liang S, Wu J, Horuzsko A, Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts, Transplantation, 86 (2008) 1125–1134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2668611</ArticleId>
            <ArticleId IdType="pubmed">18946352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Wilde V, Van Rompaey N, Hill M, Lebrun JF, Lemaitre P, Lhomme F, Kubjak C, Vokaer B, Oldenhove G, Charbonnier LM, Cuturi MC, Goldman M, Le Moine A, Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1, Am J Transplant, 9 (2009) 2034–2047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19681826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drujont L, Carretero-Iglesia L, Bouchet-Delbos L, Beriou G, Merieau E, Hill M, Delneste Y, Cuturi MC, Louvet C, Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection, PLoS One, 9 (2014) e100013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4057339</ArticleId>
            <ArticleId IdType="pubmed">24927018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, Li Y, Wu T, Na N, Zhao Y, Li W, Han C, Zhang L, Lu J, Zhao Y, TNFalpha-induced M-MDSCs promote transplant immune tolerance via nitric oxide, J Mol Med (Berl), 94 (2016) 911–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26936474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, Li Y, Zou W, Xu Y, Wang H, Wang W, Zhao Y, Adoptive transfer of IFN-gamma-induced M-MDSCs promotes immune tolerance to allografts through iNOS pathway, Inflamm Res, 68 (2019) 545–555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31055608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carretero-Iglesia L, Bouchet-Delbos L, Louvet C, Drujont L, Segovia M, Merieau E, Chiffoleau E, Josien R, Hill M, Cuturi MC, Moreau A, Comparative Study of the Immunoregulatory Capacity of In Vitro Generated Tolerogenic Dendritic Cells, Suppressor Macrophages, and Myeloid-Derived Suppressor Cells, Transplantation, 100 (2016) 2079–2089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27653226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V, Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor, Immunity, 32 (2010) 790–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20605485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou HS, Hsieh CC, Yang HR, Wang L, Arakawa Y, Brown K, Wu Q, Lin F, Peters M, Fung JJ, Lu L, Qian S, Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice, Hepatology, 53 (2011) 1007–1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3079329</ArticleId>
            <ArticleId IdType="pubmed">21374665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh CC, Chou HS, Yang HR, Lin F, Bhatt S, Qin J, Wang L, Fung JJ, Qian S, Lu L, The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells, Blood, 121 (2013) 1760–1768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3591797</ArticleId>
            <ArticleId IdType="pubmed">23299310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin J, Arakawa Y, Morita M, Fung JJ, Qian S, Lu L, C-C Chemokine Receptor Type 2-Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants, Transplantation, 101 (2017) 1793–1800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5393972</ArticleId>
            <ArticleId IdType="pubmed">27755503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arakawa Y, Qin J, Chou HS, Bhatt S, Wang L, Stuehr D, Ghosh A, Fung JJ, Lu L, Qian S, Cotransplantation with myeloid-derived suppressor cells protects cell transplants: a crucial role of inducible nitric oxide synthase, Transplantation, 97 (2014) 740–747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3997508</ArticleId>
            <ArticleId IdType="pubmed">24642686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou HS, Hsieh CC, Charles R, Wang L, Wagner T, Fung JJ, Qian S, Lu LL, Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells, Transplantation, 93 (2012) 272–282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3267010</ArticleId>
            <ArticleId IdType="pubmed">22179405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachmann B, Taylor RS, Cursiefen C, Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis, Ophthalmology, 117 (2010) 1300–1305 e1307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20605214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Wang B, Jia B, Guan J, Zeng H, Pan Z, Effects of Adoptive Transferring Different Sources of Myeloid-Derived Suppressor Cells in Mice Corneal Transplant Survival, Transplantation, 99 (2015) 2102–2108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26270448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Bei J, Zeng H, Pan Z, The roles of sepsis-induced myeloid derived suppressor cells in mice corneal, skin and combined transplantation, Transpl Immunol, 34 (2016) 8–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26733333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Y, Zhao S, Protection by LPS-induced inhibitory CD11b(+) cells on corneal allograft, Int J Clin Exp Med, 8 (2015) 4101–4107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4443150</ArticleId>
            <ArticleId IdType="pubmed">26064316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi W, Ji YW, Ham HY, Yeo A, Noh H, Jin SE, Song JS, Kim HC, Kim EK, Lee HK, Gr-1intCD11b+ myeloid-derived suppressor cells accumulate in corneal allograft and improve corneal allograft survival, J Leukoc Biol, 100 (2016) 1453–1463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27370015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren Y, Dong X, Zhao H, Feng J, Chen B, Zhou Y, Peng Y, Zhang L, Zhou Q, Li Y, Wu M, He Y, Myeloid-Derived Suppressor Cells Improve Corneal Graft Survival through Suppressing Angiogenesis and Lymphangiogenesis, Am J Transplant, (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32892499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HJ, Park SY, Jeong HJ, Kim HJ, Kim MK, Oh JY, Glucocorticoids induce corneal allograft tolerance through expansion of monocytic myeloid-derived suppressor cells, Am J Transplant, 18 (2018) 3029–3037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30019411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dilek N, Poirier N, Usal C, Martinet B, Blancho G, Vanhove B, Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5, Journal of immunology, 188 (2012) 4209–4216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22450806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng F, Chen S, Guo X, Chen Z, Huang X, Lai Y, Lin M, Clinical significance of myeloid-derived suppressor cells in human renal transplantation with acute T cell-mediated rejection, Inflammation, 37 (2014) 1799–1805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24788988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du XX, Guo YL, Zhao YP, Yang M, Chang S, Liu B, Cai LJ, Chen ZK, Accumulation of High Levels of Monocytic Myeloid-Derived Suppressor Cells Enhances Graft Survival in Almost-Tolerant Kidney Transplant Recipients, Transplant Proc, 50 (2018) 3314–3320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30577201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iglesias-Escudero M, Sansegundo-Arribas D, Riquelme P, Merino-Fernandez D, Guiral-Foz S, Perez C, Valero R, Ruiz JC, Rodrigo E, Lamadrid-Perojo P, Hutchinson JA, Ochando J, Lopez-Hoyos M, Myeloid-Derived Suppressor Cells in Kidney Transplant Recipients and the Effect of Maintenance Immunotherapy, Front Immunol, 11 (2020) 643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7203496</ArticleId>
            <ArticleId IdType="pubmed">32425928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Li J, Qi G, Tu G, Yang C, Xu M, Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy, J Transl Med, 16 (2018) 19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5789705</ArticleId>
            <ArticleId IdType="pubmed">29378596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ezzelarab MB, Perez-Gutierrez A, Humar A, Wijkstrom M, Zahorchak AF, Lu-Casto L, Wang YC, Wiseman RW, Minervini M, Thomson AW, Preliminary assessment of the feasibility of autologous myeloid-derived suppressor cell infusion in non-human primate kidney transplantation, Transpl Immunol, 56 (2019) 101225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6698203</ArticleId>
            <ArticleId IdType="pubmed">31330261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y, IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis, J Immunol, 177 (2006) 566–573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16785554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, Mastorodemos V, Plaitakis A, Sharpe A, Boumpas D, Verginis P, Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease, J Immunol, 188 (2012) 1136–1146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22210912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi H, Guo C, Yu X, Zuo D, Wang XY, Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis, J Immunol, 189 (2012) 4295–4304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3478426</ArticleId>
            <ArticleId IdType="pubmed">23034169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mildner A, Mack M, Schmidt H, Bruck W, Djukic M, Zabel MD, Hille A, Priller J, Prinz M, CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system, Brain, 132 (2009) 2487–2500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19531531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu Z, Li Y, Smith D, Doller C, Sugita S, Chan CC, Qian S, Fung J, Caspi RR, Lu L, Lin F, Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis, Invest Ophthalmol Vis Sci, 53 (2012) 959–966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3317433</ArticleId>
            <ArticleId IdType="pubmed">22247470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong HJ, Lee HJ, Ko JH, Cho BJ, Park SY, Park JW, Choi SR, Heo JW, Yoon SO, Oh JY, Myeloid-Derived Suppressor Cells Mediate Inflammation Resolution in Humans and Mice with Autoimmune Uveoretinitis, J Immunol, 200 (2018) 1306–1315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29311360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Tu Z, Qian S, Fung JJ, Markowitz SD, Kusner LL, Kaminski HJ, Lu L, Lin F, Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis, J Immunol, 193 (2014) 2127–2134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4784709</ArticleId>
            <ArticleId IdType="pubmed">25057008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Wang S, Huang Y, Wang H, Zhao J, Gaskin F, Yang N, Fu SM, Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation, Clin Immunol, 157 (2015) 175–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4657752</ArticleId>
            <ArticleId IdType="pubmed">25680967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, Li Y, Liu H, Yu X, Wang H, Li J, Li Z, Wang XY, Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis, Ann Rheum Dis, 75 (2016) 278–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4418961</ArticleId>
            <ArticleId IdType="pubmed">25371442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajabinejad M, Salari F, Gorgin Karaji A, Rezaiemanesh A, The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells?, Artif Cells Nanomed Biotechnol, 47 (2019) 4149–4158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31698956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park MJ, Lee SH, Kim EK, Lee EJ, Baek JA, Park SH, Kwok SK, Cho ML, Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice, Sci Rep, 8 (2018) 3753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5830490</ArticleId>
            <ArticleId IdType="pubmed">29491381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Huang Y, Wang S, Fu R, Guo C, Wang H, Zhao J, Gaskin F, Chen J, Yang N, Fu SM, Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts, J Autoimmun, 65 (2015) 82–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4679657</ArticleId>
            <ArticleId IdType="pubmed">26318644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Zhang Z, Zhang H, Wu M, Wang Y, Myeloid-derived suppressor cells protect mouse models from autoimmune arthritis via controlling inflammatory response, Inflammation, 37 (2014) 670–677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24264477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurko J, Vida A, Ocsko T, Tryniszewska B, Rauch TA, Glant TT, Szekanecz Z, Mikecz K, Suppression of proteoglycan-induced autoimmune arthritis by myeloid-derived suppressor cells generated in vitro from murine bone marrow, PLoS One, 9 (2014) e111815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4219784</ArticleId>
            <ArticleId IdType="pubmed">25369029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujii W, Ashihara E, Hirai H, Nagahara H, Kajitani N, Fujioka K, Murakami K, Seno T, Yamamoto A, Ishino H, Kohno M, Maekawa T, Kawahito Y, Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis, J Immunol, 191 (2013) 1073–1081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23804709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu D, Tian J, Wu X, Li M, Tang X, Rui K, Guo H, Ma J, Xu H, Wang S, G-MDSC-derived exosomes attenuate collagen-induced arthritis by impairing Th1 and Th17 cell responses, Biochim Biophys Acta Mol Basis Dis, 1865 (2019) 165540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31470074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegde VL, Nagarkatti PS, Nagarkatti M, Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol, PLoS One, 6 (2011) e18281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3069975</ArticleId>
            <ArticleId IdType="pubmed">21483776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Czaja AJ, Adoptive cell transfer in autoimmune hepatitis, Expert Rev Gastroenterol Hepatol, 9 (2015) 821–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25719553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan Q, Moreno S, Qing G, Weiss CR, Lu L, Bernstein CN, Warrington RJ, Ma Y, Peng Z, The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis, J Leukoc Biol, 94 (2013) 803–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23901119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haile LA, von Wasielewski R, Gamrekelashvili J, Kruger C, Bachmann O, Westendorf AM, Buer J, Liblau R, Manns MP, Korangy F, Greten TF, Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway, Gastroenterology, 135 (2008) 871–881,  881 e871–875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18674538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang R, Ito S, Nishio N, Cheng Z, Suzuki H, Isobe KI, Dextran sulphate sodium increases splenic Gr1(+)CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation, Clin Exp Immunol, 164 (2011) 417–427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3087938</ArticleId>
            <ArticleId IdType="pubmed">21413942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, Papalois A, Pikoulis E, The TNBS-induced colitis animal model: An overview, Ann Med Surg (Lond), 11 (2016) 9–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5021709</ArticleId>
            <ArticleId IdType="pubmed">27656280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO, Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice, Gastroenterology, 107 (1994) 1643–1652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7958674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Touw W, Kang K, Luan Y, Ma G, Mai S, Qin L, Bian G, Zhang R, Mungamuri SK, Hu HM, Zhang CC, Aaronson SA, Feldmann M, Yang WC, Chen SH, Pan PY, Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B, J Immunol, 201 (2018) 1727–1734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6379207</ArticleId>
            <ArticleId IdType="pubmed">30068593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim CH, Yoo JK, Jeon SH, Lim CY, Lee JH, Koo DB, Park MY, Anti-psoriatic effect of myeloid-derived suppressor cells on imiquimod-induced skin inflammation in mice, Scand J Immunol, 89 (2019) e12742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30548969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marhaba R, Vitacolonna M, Hildebrand D, Baniyash M, Freyschmidt-Paul P, Zoller M, The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema, J Immunol, 179 (2007) 5071–5081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17911592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong AW, Read C, Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review, JAMA, 323 (2020) 1945–1960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32427307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M, British Association of Dermatologists’ guidelines for the management of alopecia areata 2012, Br J Dermatol, 166 (2012) 916–926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22524397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin B, Ma G, Yen CY, Zhou Z, Wang GX, Divino CM, Casares S, Chen SH, Yang WC, Pan PY, Myeloid-derived suppressor cells prevent type 1 diabetes in murine models, J Immunol, 185 (2010) 5828–5834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4355963</ArticleId>
            <ArticleId IdType="pubmed">20956337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H, Zhen Y, Ma Z, Li H, Yu J, Xu ZG, Wang XY, Yi H, Yang YG, Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus, Sci Transl Med, 8 (2016) 331ra340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4895207</ArticleId>
            <ArticleId IdType="pubmed">27009269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji J, Xu J, Zhao S, Liu F, Qi J, Song Y, Ren J, Wang T, Dou H, Hou Y, Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and Tregs, Clin Sci (Lond), 130 (2016) 1453–1467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27231253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong G, Yang Y, Li X, Yao X, Zhu Y, Zhang H, Wang H, Ma Q, Zhang J, Shi H, Ning Z, Yan F, Zhai W, Dai J, Li Z, Li C, Ming J, Xue Q, Meng X, Si C, Xiong H, Granulocytic myeloid-derived suppressor cells contribute to IFN-I signaling activation of B cells and disease progression through the lncRNA NEAT1-BAFF axis in systemic lupus erythematosus, Biochim Biophys Acta Mol Basis Dis, 1866 (2020) 165554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31513833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji J, Li P, Shen C, Dou H, Wang T, Shi L, Hou Y, MDSCs: friend or foe in systemic lupus erythematosus, Cell Mol Immunol, 16 (2019) 937–939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6884520</ArticleId>
            <ArticleId IdType="pubmed">31431693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lourenco EV, Wong M, Hahn BH, Palma-Diaz MF, Skaggs BJ, Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells, Arthritis Rheumatol, 66 (2014) 674–685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24574228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma H, Wan S, Xia CQ, Immunosuppressive CD11b+Ly6Chi monocytes in pristane-induced lupus mouse model, J Leukoc Biol, 99 (2016) 1121–1129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26657791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park MJ, Lee SH, Kim EK, Lee EJ, Park SH, Kwok SK, Cho ML, Myeloid-Derived Suppressor Cells Induce the Expansion of Regulatory B Cells and Ameliorate Autoimmunity in the Sanroque Mouse Model of Systemic Lupus Erythematosus, Arthritis Rheumatol, 68 (2016) 2717–2727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27214349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park YS, Gauna AE, Cha S, Mouse Models of Primary Sjogren’s Syndrome, Curr Pharm Des, 21 (2015) 2350–2364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4425610</ArticleId>
            <ArticleId IdType="pubmed">25777752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi J, Li D, Shi G, Zhang X, Pan Y, Dou H, Yao G, Hou Y, Myeloid-derived suppressor cells exacerbate Sjogren’s syndrome by inhibiting Th2 immune responses, Mol Immunol, 101 (2018) 251–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30029059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatt S, Shen GQ, Li Y, Qian S, Ragni MV, Lu L, Hepatic stellate cell-conditioned myeloid cells provide a novel therapy for prevention of factor VIII antibody formation in mice, Exp Hematol, 43 (2015) 277–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25534204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P, Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells, Blood, 118 (2011) 5498–5505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3217352</ArticleId>
            <ArticleId IdType="pubmed">21972293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S, Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells, Cancer research, 67 (2007) 4507–4513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17483367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obermajer N, Kalinski P, Generation of myeloid-derived suppressor cells using prostaglandin E2, Transplant Res, 1 (2012) 15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3560989</ArticleId>
            <ArticleId IdType="pubmed">23369567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enderby C, Keller CA, An overview of immunosuppression in solid organ transplantation, Am J Manag Care, 21 (2015) s12–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25734416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cropley A, Weltman M, The use of immunosuppression in autoimmune hepatitis: A current literature review, Clin Mol Hepatol, 23 (2017) 22–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5381833</ArticleId>
            <ArticleId IdType="pubmed">28288505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scalea JR, Lee YS, Davila E, Bromberg JS, Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation, Transplantation, 102 (2018) 359–367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6890230</ArticleId>
            <ArticleId IdType="pubmed">29189485</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
